Regulators support C-Path's skeletal muscle biomarkers

FDA and EMA issued Letters of Support for four skeletal muscle biomarkers identified by the Predictive Safety Testing Consortium (PSTC) of the Critical Path Institute (C-Path).

Elevated levels of myosin light chain 3 ( MYL3), skeletal muscle troponin I (sTn1), fatty acid binding protein 3 (FABP3) and muscle-type creatine kinase (CK-M) in blood were associated with skeletal muscle degeneration/necrosis in C-Path's rat studies. ...